AC Immune SA announced positive interim results from its ongoing Phase 1b/2a clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment…
Mesoblast announced results from a Phase 3 trial of its allogeneic mesenchymal precursor cell (MPC) therapy rexlemestrocel-L in patients with chronic low back pain (CLBP)…
Concert Pharmaceuticals reported that its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint…
Biogen announced in its annual results and earnings presentation that its Phase II SPARK study of cinpanemab (BIIB054), under development for Parkinson’s disease, missed its primary and…
BioHaven Pharmaceuticals announced the outcome from a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as…
Patients with Parkinson’s disease who are treated with deep brain stimulation (DBS) generally have unpredictable and varied speech outcomes after DBS surgery. Their speech can…
The Uniformed Services University and the National Institutes of Health led a study with eyebrow raising results: that the cause of lingering symptoms associated with…
Eli Lilly reported positive results from its Phase II TRAILBLAZER-ALZ trial, which showed treatment with donanemab resulted in significant slowing of decline in a composite…
Could it be that COVID-19 impacts the brain via microvascular blood vessel damage but not by direct viral infection? That’s the likely explanation based on recent…
NeuroGenesis and Hadassah Medical Center announced highly positive results from a placebo-controlled Phase 2 clinical trial assessing the impact of NG-01 autologous proprietary subpopulation of…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
